DOI QR코드

DOI QR Code

Clinical utility of chromosomal microarray analysis to detect copy number variants: Experience in a single tertiary hospital

  • Park, Hee Sue (Department of Laboratory Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine) ;
  • Kim, Aryun (Department of Neurology, Chungbuk National University Hospital, Chungbuk National University College of Medicine) ;
  • Shin, Kyeong Seob (Department of Laboratory Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine) ;
  • Son, Bo Ra (Department of Laboratory Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine)
  • 투고 : 2021.04.29
  • 심사 : 2021.06.13
  • 발행 : 2021.06.30

초록

Purpose: To summarize the results of chromosomal microarray analysis (CMA) for copy number variants (CNVs) detection and clinical utility in a single tertiary hospital. Materials and Methods: We performed CMA in 46 patients over the course of two years. Detected CNVs were classified into five categories according to the American College of Medical Genetics and Genomics guidelines and correlated with clinical manifestations. Results: A total of 31 CNVs were detected in 19 patients, with a median CNV number per patient of two CNVs. Among these, 16 CNVs were classified as pathogenic (n=3) or likely pathogenic (LP) (n=11) or variant of uncertain significance (n=4). The 16p11.2 deletion and 16p13.11 deletion classified as LP were most often detected in 6.5% (3/46), retrospectively. CMA diagnostic yield was 24.3% (9/37 patients) for symptomatic patients. The CNVs results of the commercial newborn screening test using next generation sequencing platforms showed high concordance with CMA results. Conclusion: CMA seems useful as a first-tier test for developmental delay with or without congenital anomalies. However, the classification and interpretation of CMA still remained a challenge. Further research is needed for evidence-based interpretation.

키워드

참고문헌

  1. Bi W, Borgan C, Pursley AN, Hixson P, Shaw CA, Bacino CA, et al. Comparison of chromosome analysis and chromosomal microarray analysis: what is the value of chromosome analysis in today's genomic array era? Genet Med 2013;15:450-7. https://doi.org/10.1038/gim.2012.152
  2. Freeman JL, Perry GH, Feuk L, Redon R, McCarroll SA, Altshuler DM, et al. Copy number variation: new insights in genome diversity. Genome Res 2006;16:949-61. https://doi.org/10.1101/gr.3677206
  3. Haraksingh RR, Abyzov A, Urban AE. Comprehensive performance comparison of high-resolution array platforms for genome-wide Copy Number Variation (CNV) analysis in humans. BMC Genomics 2017;18:321. https://doi.org/10.1186/s12864-017-3658-x
  4. Riggs ER, Wain KE, Riethmaier D, Smith-Packard B, Faucett WA, Hoppman N, et al. Chromosomal microarray impacts clinical management. Clin Genet 2014;85:147-53. https://doi.org/10.1111/cge.12107
  5. Kaminsky EB, Kaul V, Paschall J, Church DM, Bunke B, Kunig D, et al. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet Med 2011;13:777-84. https://doi.org/10.1097/GIM.0b013e31822c79f9
  6. Zarrei M, MacDonald JR, Merico D, Scherer SW. A copy number variation map of the human genome. Nat Rev Genet 2015;16:172-83. https://doi.org/10.1038/nrg3871
  7. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med 2020;22:245-57. https://doi.org/10.1038/s41436-019-0686-8
  8. Jang W, Kim Y, Han E, Park J, Chae H, Kwon A, et al. Chromosomal microarray analysis as a first-tier clinical diagnostic test in patients with developmental delay/intellectual disability, autism spectrum disorders, and multiple congenital anomalies: a prospective multicenter study in Korea. Ann Lab Med 2019;39:299-310. https://doi.org/10.3343/alm.2019.39.3.299
  9. Yao R, Yu T, Qing Y, Wang J, Shen Y. Evaluation of copy number variant detection from panel-based next-generation sequencing data. Mol Genet Genomic Med 2019;7:e00513. https://doi.org/10.1002/mgg3.513
  10. Moreno-Cabrera JM, Del Valle J, Feliubadalo L, Pineda M, Gonzalez S, Campos O, et al. Screening of CNVs using NGS data improves mutation detection yield and decreases costs in genetic testing for hereditary cancer. J Med Genet 2020, in press.
  11. Srour M, Shevell M. Genetics and the investigation of developmental delay/intellectual disability. Arch Dis Child 2014;99:386-9. https://doi.org/10.1136/archdischild-2013-304063
  12. Steinman KJ, Spence SJ, Ramocki MB, Proud MB, Kessler SK, Marco EJ, et al.; Simons VIP Consortium. 16p11.2 Deletion and duplication: characterizing neurologic phenotypes in a large clinically ascertained cohort. Am J Med Genet A 2016;170:2943-55. https://doi.org/10.1002/ajmg.a.37820
  13. Kendall KM, Bracher-Smith M, Fitzpatrick H, Lynham A, Rees E, Escott-Price V, et al. Cognitive performance and functional outcomes of carriers of pathogenic copy number variants: analysis of the UK Biobank. Br J Psychiatry 2019;214:297-304. https://doi.org/10.1192/bjp.2018.301
  14. Rosenfeld JA, Coe BP, Eichler EE, Cuckle H, Shaffer LG. Estimates of penetrance for recurrent pathogenic copy-number variations. Genet Med 2013;15:478-81. https://doi.org/10.1038/gim.2012.164
  15. Wang R, Zhang H, Li L, Yue F, Jiang Y, Li S, et al. Prenatal detection of interstitial 18p11.31-p11.22 microduplications: phenotypic diversity and literature review. Prenat Diagn 2019;39:1120-6. https://doi.org/10.1002/pd.5553